“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an ...

Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.

The stock's fall snapped a three-day winning streak.

Stryker Corporation (NYSE:SYK), a leading player in the medical technology industry with a substantial market capitalization of $149 billion, has been making waves with its strong financial ...

In a report released today, Michael Matson from Needham reiterated a Buy rating on Stryker (SYK – Research Report), with a price target of ...

Analyst Patrick Wood from Morgan Stanley maintained a Buy rating on Stryker (SYK – Research Report) and keeping the price target at ...

Shares of Stryker Corp. SYK slid 1.03% to $391.07 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.47% to 6,039.31 and Dow ...

Stryker beat Wall Street estimates for fourth-quarter profit and forecast 2025 earnings largely above expectations on Tuesday, fueled by strong demand for its medical and surgical devices.

Smith & Nephew's stock has underperformed, driven by ongoing market share losses in hip and knee markets and pricing ...

Here are eight things for ASCs to know about the sale: 1. Stryker's U.S. spine segment will be sold to investment firm Viscogliosi Brothers. 2. That group will create VB Spine, which will be a ...

Stryker Corporation SYK recently announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi ...

On Tuesday, Stryker Corp (SYK) stock saw a decline, ending the day at $395.15 which represents a decrease of $-4.75 or -1.19% from the prior close of $399.9. The stock opened at $400.61 and touched a ...